National Center for Tumor Diseases

Running trials

• Recruiting

  Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer

  NCT07860047· Phase 2· University Hospital Tuebingen· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· UroTrials GmbH· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer

  2025-521128-31-00· Phase 1/2· Genentech Inc.· Source

• Recruiting

  Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

  NCT07148193· Technische Universität Dresden· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· Phase 2· GBG Forschungs GmbH· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

  NCT06631092· Phase 1/2· NEC Bio B.V· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· UroTrials Company (GmbH)· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

  NCT05676203· Phase 3· Jena University Hospital· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Gilead Sciences· Source

• Recruiting

  Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

  NCT05009082· Phase 3· AGO Study Group· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

  NCT05306340· Phase 3· Genentech, Inc.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

  NCT05050942· Phase 3· Camurus AB· Source

• Active, not recruiting

  Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer

  NCT04784714· Phase 3· AstraZeneca AB· Source

• Active, not recruiting

  This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN)

  NCT04592913· Phase 3· Astrazeneca AB· Source

• Active, not recruiting

  A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

  NCT04534205· Phase 2/3· BioNTech SE· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· PMV Pharmaceuticals, Inc· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

  NCT04503278· Phase 1· BioNTech Cell & Gene Therapies GmbH· Source

• Recruiting

  CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

  NCT05652569· German Cancer Research Center· Source

• Recruiting

  Praegnant Breast Cancer: Early/Advanced/Metastatic

  NCT02338167· University Hospital Tuebingen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer7 recruiting
• Prostate cancer6 recruiting
• Colorectal cancer3 recruiting
• Childhood cancers2 recruiting
• Liver and biliary tract cancer2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

  2024-512670-10-00· Phase 1/2· BioInvent International AB· Source

• Completed

  A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

  NCT05571839· Phase 1· Seagen Inc.· Source

• Completed

  Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

  NCT05092360· Phase 3· Mural Oncology Inc.· Source

• Active, not recruiting

  A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

  NCT05104866· Phase 3· AstraZeneca AB· Source

• Completed

  Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

  NCT04811027· Phase 2· Immutep S.A.S.· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Australasian Gastro-Intestinal Trials Group· Source

• Active, not recruiting

  Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

  NCT04417621· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Elevar Therapeutics· Source

• Active, not recruiting

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  NCT04191499· Phase 2/3· Hoffmann-La Roche· Source

• Active, not recruiting

  Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  NCT03937219· Phase 3· Exelixis· Source

• Active, not recruiting

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma62 works · 3 trials
• Sarcoma47 works · 1 trial
• Glioblastoma30 works · 0 trials
• Acute myeloid leukaemia21 works · 0 trials
• Triple-negative breast cancer20 works · 3 trials
• Brain metastases14 works · 0 trials
• Childhood cancers12 works · 3 trials